drugset
drugset / Trial / NCT05066724

Efficacy of Centanafadine SR as a Potential Smoking Cessation Treatment

NCT05066724 ↗

Phase 2 Completed 50 enrolled Otsuka Pharmaceutical Development & Commercialization, Inc.
NaSingle-groupOpen-labelTreatment

Summary

This study will explore the efficacy and tolerability of centanafadine at a dose of 400 mg per day of centanafadine in promoting smoking abstinence in adult smokers seeking to quit.

Timeline

Start
2021-09-15
Primary completion
2022-05-31
Completion
2022-05-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Centanafadine Small molecule 200 mg Oral

Indications

No indication recorded.